Skip to main content

Funding Opportunities

The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities below and streamline your search by using keyword or type of funding.

Highlighted Topics

Title	Posted Date	Expiration Date
Research on Rare Cancers Across the Cancer Control Continuum	February 20, 2026	February 20, 2028
Advancing Nanotechnology Research to Improve Diagnosis and Treatment Options	March 10, 2026	March 10, 2028
Advancing Toward a Cure for Acquired Neuropathy	April 6, 2026	April 6, 2028
Advancing Mechanism-driven Translational Research of Beneficial and Detrimental Effect of Psilocybin on Cancer and Other Health Conditions	April 10, 2026	April 10, 2028
GLP-1s: Implications for Nutritional Status and Metabolic Health	April 24, 2026	April 24, 2028

Note: Highlighted topics have replaced Notice of Special Interest Announcements.

Please also check the “Other Notices” tab on the NIH Guide for Grants and Contracts to see updates to NIH policies that ensure alignment with the Administration’s priorities.

Notice of Funding Opportunities

Title	Announcement Number	Activity Code	Clinical Trials Status	Expiration Date Sort descending	Program Official
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes	PAR-25-095 (R01 Clinical Trial Not Allowed)	R01	Clinical Trial Not Allowed	09/07/2026	Wendy Wang, Ph.D., M.Sc.
Assay Validation of High Quality Markers for Clinical Studies in Cancer	PAR-25-074 (UH2/UH3 Clinical Trial Not Allowed)	UH2, UH3	Clinical Trial Not Allowed	10/14/2026	Sudhir Srivastava, Ph.D., M.P.H.
Assay Validation of High Quality Markers for Clinical Studies in Cancer	PAR-25-075 (UH3 Clinical Trials Not Allowed)	UH3		10/14/2026	Sudhir Srivastava, Ph.D., M.P.H.
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers	PAR-23-286 (K99/R00 - Independent Clinical Trial Not Allowed)	R00, K99	Clinical Trial Not Allowed	10/15/2026	Asad Umar, D.V.M., Ph.D.
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers	PAR-23-287 (K99/R00 - Independent Clinical Trial Required)	R00, K99	Clinical Trial Required	10/15/2026	Asad Umar, D.V.M., Ph.D.
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers	PAR-23-288 (K99/R00 - Independent Basic Experimental Studies with Humans Required)	R00, K99		10/15/2026	Asad Umar, D.V.M., Ph.D.
Cancer Prevention and Control Clinical Trials Grant Program	PAR-25-167 (R01 Clinical Trial Required)	R01	Clinical Trial Required	01/07/2027	Goli Samimi, Ph.D., M.P.H.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics	PAR-25-070 (R21 Clinical Trial Not Allowed)	R21	Clinical Trial Not Allowed	01/07/2027	Edward Sauter, M.D., Ph.D.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics	PAR-25-069 (R01 Clinical Trial Optional)	R01	Clinical Trial Optional	01/07/2027	Edward Sauter, M.D., Ph.D.
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis	PAR-25-081 (R01 Clinical Trial Required)	R01	Clinical Trial Required	01/07/2027	Brandy Heckman-Stoddard, Ph.D., M.P.H.